Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.

Dietary energy restriction (DER) has been well established as a potent anticancer strategy. Non-adoption of restricted diet for an extended period has limited its practical implementation in humans with a compelling need to develop agents that mimic effects similar to DER, without reduction in actua...

Full description

Bibliographic Details
Main Authors: Saurabh Singh, Sanjay Pandey, Anant Narayan Bhatt, Richa Chaudhary, Vikas Bhuria, Namita Kalra, Ravi Soni, Bal Gangadhar Roy, Daman Saluja, Bilikere S Dwarakanath
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4489743?pdf=render
id doaj-c6b3170db061492b9bf5bfdaaa3aa3be
record_format Article
spelling doaj-c6b3170db061492b9bf5bfdaaa3aa3be2020-11-25T02:47:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013208910.1371/journal.pone.0132089Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.Saurabh SinghSanjay PandeyAnant Narayan BhattRicha ChaudharyVikas BhuriaNamita KalraRavi SoniBal Gangadhar RoyDaman SalujaBilikere S DwarakanathDietary energy restriction (DER) has been well established as a potent anticancer strategy. Non-adoption of restricted diet for an extended period has limited its practical implementation in humans with a compelling need to develop agents that mimic effects similar to DER, without reduction in actual dietary intake. Glycolytic inhibitor, 2-deoxy-D-glucose (2-DG), has recently been shown to possess potential as an energy restriction mimetic agent (ERMA). In the present study we evaluated the effect of dietary 2-DG administration on a mouse tumor model, with a focus on several potential mechanisms that may account for the inhibition of tumorigenesis.Swiss albino strain 'A' mice were administered with 0.2% and 0.4% w/v 2-DG in drinking water for 3 months prior to tumor implantation (Ehrlich's ascites carcinoma; EAC) and continued till the termination of the study with no adverse effects on general physiology and animal growth. Dietary 2-DG significantly reduced the tumor incidence, delayed the onset, and compromised the tumor growth along with enhanced survival. We observed reduced blood glucose and serum insulin levels along with decreased proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine positive (BrdU+) tumor cells in 2-DG fed mice. Also, reduced levels of certain key players of metabolic pathways such as phosphatidylinositol 3-kinase (PI3K), phosphorylated-Akt and hypoxia inducible factor-1 alpha (HIF-1α) were also noted in tumors of 2-DG fed mice. Further, decrease in CD4+/CD8+ ratio and T-regulatory cells observed in 2-DG fed mice suggested enhanced antitumor immunity and T cell effector function.These results strongly suggest that dietary 2-DG administration in mice, at doses easily achievable in humans, suitably modulates several pleotrophic factors mimicking DER and inhibits tumorigenesis, emphasizing the use of ERMAs as a promising cancer preventive strategy.http://europepmc.org/articles/PMC4489743?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Saurabh Singh
Sanjay Pandey
Anant Narayan Bhatt
Richa Chaudhary
Vikas Bhuria
Namita Kalra
Ravi Soni
Bal Gangadhar Roy
Daman Saluja
Bilikere S Dwarakanath
spellingShingle Saurabh Singh
Sanjay Pandey
Anant Narayan Bhatt
Richa Chaudhary
Vikas Bhuria
Namita Kalra
Ravi Soni
Bal Gangadhar Roy
Daman Saluja
Bilikere S Dwarakanath
Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
PLoS ONE
author_facet Saurabh Singh
Sanjay Pandey
Anant Narayan Bhatt
Richa Chaudhary
Vikas Bhuria
Namita Kalra
Ravi Soni
Bal Gangadhar Roy
Daman Saluja
Bilikere S Dwarakanath
author_sort Saurabh Singh
title Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
title_short Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
title_full Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
title_fullStr Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
title_full_unstemmed Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice.
title_sort chronic dietary administration of the glycolytic inhibitor 2-deoxy-d-glucose (2-dg) inhibits the growth of implanted ehrlich's ascites tumor in mice.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Dietary energy restriction (DER) has been well established as a potent anticancer strategy. Non-adoption of restricted diet for an extended period has limited its practical implementation in humans with a compelling need to develop agents that mimic effects similar to DER, without reduction in actual dietary intake. Glycolytic inhibitor, 2-deoxy-D-glucose (2-DG), has recently been shown to possess potential as an energy restriction mimetic agent (ERMA). In the present study we evaluated the effect of dietary 2-DG administration on a mouse tumor model, with a focus on several potential mechanisms that may account for the inhibition of tumorigenesis.Swiss albino strain 'A' mice were administered with 0.2% and 0.4% w/v 2-DG in drinking water for 3 months prior to tumor implantation (Ehrlich's ascites carcinoma; EAC) and continued till the termination of the study with no adverse effects on general physiology and animal growth. Dietary 2-DG significantly reduced the tumor incidence, delayed the onset, and compromised the tumor growth along with enhanced survival. We observed reduced blood glucose and serum insulin levels along with decreased proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine positive (BrdU+) tumor cells in 2-DG fed mice. Also, reduced levels of certain key players of metabolic pathways such as phosphatidylinositol 3-kinase (PI3K), phosphorylated-Akt and hypoxia inducible factor-1 alpha (HIF-1α) were also noted in tumors of 2-DG fed mice. Further, decrease in CD4+/CD8+ ratio and T-regulatory cells observed in 2-DG fed mice suggested enhanced antitumor immunity and T cell effector function.These results strongly suggest that dietary 2-DG administration in mice, at doses easily achievable in humans, suitably modulates several pleotrophic factors mimicking DER and inhibits tumorigenesis, emphasizing the use of ERMAs as a promising cancer preventive strategy.
url http://europepmc.org/articles/PMC4489743?pdf=render
work_keys_str_mv AT saurabhsingh chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT sanjaypandey chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT anantnarayanbhatt chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT richachaudhary chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT vikasbhuria chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT namitakalra chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT ravisoni chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT balgangadharroy chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT damansaluja chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
AT bilikeresdwarakanath chronicdietaryadministrationoftheglycolyticinhibitor2deoxydglucose2dginhibitsthegrowthofimplantedehrlichsascitestumorinmice
_version_ 1724754781704028160